trial

Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia

NCTId NCT00825539
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Completed
Enrollment 68 (actual)
Sponsored by Novartis Pharmaceuticals
Primary completion 2011-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Completed
Enrollment
68 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2009-01
Primary completion
2011-11
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
AQW051

Sponsors

Novartis PharmaceuticalsLead Sponsor

Sites

7 total
Los Angeles, United StatesChicago, United StatesBaltimore, United StatesBoston, United StatesSt Louis, United StatesNew York, United StatesButner, United States

Linked catalysts

1
Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia — primary completion2011-11

Facts & assertions

4 sourced
Enrollment
68
Phase
PHASE1,PHASE2
Primary Completion Date
2011-11
Status
COMPLETED
relationships
The graph out of here
drug
AQW051
drug
lead_sponsor
Novartis Pharmaceuticals
company
indication
Schizophrenia
indication
Bipolar Disorder
indication
Schizophrenia
indication